Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Patheon | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Patheon

Drug Substance Services up 26% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Patheon

3Q Revenues: $482.0 million (+8%)

3Q Earnings: $8.8 million (loss of $21.6 million 3Q15)

YD Revenues: $1.4 billion (+3%)

YTD Loss: $12.4 million (loss of $9.0 million YTD15)

Comments: Drug Product Services (DPS) segment revenue was $309 million in the quarter, up 7% with growth in North America. Pharmaceutical Development Services (PDS) segment revenue was $57 million, up 6% with growth across the network, partially offset by the delay of additional sterile capacity coming online at the company’s Greenville, NC site. Drug Substance Services (DSS) segment revenue was $116 million, up 26% driven by both small and large molecule services, with Biologics accounting for approximately 40% of the segment.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters